[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-pain":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,46,76,106,142,164,189,217,244,271,302,330,351,379,400,426,450,472,493,528,549,575,603,637,660],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100635192","human-experimental-models-of-pain-hemp-100635192",false,"NCT07549490","Human Experimental Models of Pain (HEMP)","A Pilot Study for Developing a Comprehensive Signal Detection Approach for the Mechanisms of Action and Analgesic Efficacy of Two Analgesics Using Human Experimental Models of Pain (HEMP)","* INCLUSION CRITERIA:\n\nFor an individual to be eligible to participate in this study, they must meet all of the following criteria:\n\n* Voluntarily consent to participate and provide written informed consent prior to the start of any study-specific procedures.\n* Read and speak English fluently.\n* State willingness to comply with all study procedures and availability for the duration of the study.\n* Are not pregnant or breastfeeding.\n* Are 18 or older years of age at screening.\n* Have a skin type score between 2 and 5 (inclusive) on the Fitzpatrick Scale.\n* Must correctly identify at least nine out of 12 temperatures (32 degrees Celsius, 38 degrees Celsius, 44 degrees Celsius, and 50 degrees Celsius, each presented three times) during the sensory discrimination test at screening.\n* Provide a verbal pain rating between 4 and 9 (inclusive) during the intradermal capsaicin challenge at screening. The study team will verify tolerability, and participants will continue only after it has been confirmed.\n* During the cold pressor test at screening, provide a verbal pain rating between 4 and 9 (inclusive) and keep one hand completely immersed in ice-cold water (1-4 degrees Celsius) between 1 and 4 minutes (inclusive). The study team will verify tolerability, and participants will continue only after it has been confirmed.\n* Are able to learn and perform all quantitative sensory testing QST procedures (see the separate QST manual).\n* Have the ability to take oral medication and be willing to adhere to the study intervention regimen.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Have a history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the participant or the validity of the study results.\n* Have alcohol or drug dependence (excluding nicotine and caffeine) within the past 2 years, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM IV-TR) and\u002For participants who have ever been in a substance or alcohol rehabilitation program to treat their substance dependence are currently seeking such treatment.\n* Have a clinically significant abnormal finding on the physical exam, medical history, or clinical laboratory results at screening.\n* Have a history of psychotic reactions, a non-psychotic emotional disorder, or another mental illness that, in the opinion of the investigator, may affect the ability of the participant to participate in the study.\n* Have recent history of suicidal ideation or suicidal behavior within the past 6 months, as assessed by the Columbia- Suicide Severity Rating Scale (C-SSRS) at screening (baseline version) or at check-in ( Since Last Visit version).\n* Have a history of allergy or hypersensitivity to pregabalin or other gabapentinoids, naproxen or other NSAIDs, or another ingredient in the study drugs, or anything else that, in the opinion of the Investigator, could put the participant at risk.\n* Have participated in another clinical trial (randomized participants only) within 30 days prior to the first dose of study medication.\n* Use any prescription medication, except hormonal contraceptive or hormonal replacement therapy, from 14 days prior to the first dose of study medication until study participation has ended without evaluation and approval by the Investigator.\n* Donate blood or plasma within 30 days prior to the first dose of study medication until the end of study participation. It is recommended that participants not donate blood or plasma until at least 30 days after their study participation has ended.\n* Female participants who are currently pregnant or breastfeeding, or who are planning to become pregnant during the study or within 30 days after the last study drug administration.\n* Show a positive urine alcohol test at screening.\n* Have smoked or used tobacco- or nicotine-containing products within 30 days prior to the first dose of study treatment until the end of the study.\n* Have an allergy to capsaicin or another capsaicinoid.\n* Have a tattoo, excessive scarring or discoloration, keloid formation, or, at the Investigator s discretion, otherwise unhealthy skin (e.g., eczema, psoriasis, burn, and cut) at a QST site.\n* Have a significant history of nerve injury or damage at a QST site, at the Investigator s discretion.\n* Participants who report any stimulus as intolerable at any point during the screening procedures will be excluded from participation.",true,"ALL","18 Years","100 Years",{"count":7,"type":22},"ESTIMATED","INTERVENTIONAL",[25],"NA","This pilot study will test an innovative way to establish how pain medicines provide analgesia in healthy adults. The study uses a group of short, controlled pain tests to look at different types of pain responses in the body. The main goal is to find out if this testing approach can show the pain-relieving effects of 2 medicines, pregabalin and naproxen versus placebo, and show how they provide relief of different types of pain.\n\nThe study hypothesis is that this pain testing approach administered as a battery would be able to tell the difference between a medicine that works mainly in the brain and spinal cord (pregabalin) and a medicine that works mainly on inflammation in body tissues (naproxen).\n\nUp to 25 healthy adults will take part. Each participant will receive all 3 study treatments, pregabalin, naproxen, and placebo, administered in random order during separate study periods. The order will be assigned by chance. Neither the participant nor the study team will know which treatment is given at each visit.\n\nThe study includes several experimental pain tests. These include:\n\na heat and capsaicin skin test that causes short-term skin sensitivity,\n\na UVB light test that causes a temporary sunburn-like sensitivity, and\n\na cold pressor test, in which a hand is placed in very cold water for a short time.\n\nParticipants will also have sensory testing to measure how they feel touch, pressure, pinprick, warmth, heat, and cold. Blood samples will be collected to measure study drug levels. Urine samples, vital signs, and other safety checks will also be done.\n\nEach treatment visit includes testing before and for several hours after taking the study drug. There will be a washout period of at least 48 hours between treatments. Total participation may last up to about 10 weeks.\n\nThis study is not expected to provide direct medical benefit to participants. The information learned may help researchers improve early testing of future pain treatments....",[28],"Acute Pain",[30,31,32],"Human Experimental Models of Pain","HCM (Heat\u002FCapsaicin Pain Model)","Pain Mechanisms","NOT_YET_RECRUITING","2026-08-20",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":22},"2026-08-26",{"date":41,"type":22},"2030-12-31",{"name":43,"class":44},"National Center for Complementary and Integrative Health (NCCIH)","NIH",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100643043","the-effect-of-rhythmc-skn-tappng-and-internal-vbraton-appled-proxmal-to-the-procedure-ste-on-pan-and-fear-percepton-durng-pedatrc-perpheral-venpuncture-100643043","NCT07650591","THE EFFECT OF 'RHYTHMİC SKİN TAPPİNG' AND INTERNAL VİBRATİON APPLİED PROXİMAL TO THE PROCEDURE SİTE ON PAİN AND FEAR PERCEPTİON DURİNG PEDİATRİC PERİPHERAL VENİPUNCTURE","THE EFFECT OF 'RHYTHMİC SKİN TAPPİNG' AND INTERNAL VİBRATİON APPLİED PROXİMAL TO THE PROCEDURE SİTE ON PAİN AND FEAR PERCEPTİON DURİNG PEDİATRİC PERİPHERAL VENİPUNCTURE: A RANDOMİZED CONTROLLED TRİAL","Inclusion Criteria:\n\n* Being between 6 and 12 years of age\n\nRequiring a peripheral venipuncture procedure\n\nHaving written informed consent from the parents\n\nHaving verbal assent from the child\n\nBeing able to speak and understand Turkish\n\nHaving a cognitive development level appropriate for age\n\nAbsence of any chronic pain condition\n\nExclusion Criteria:\n\n* Refusing to participate in the study or wishing to withdraw at any stage\n\nDevelopment of complications during the procedure\n\nHaving used analgesics within the last 24 hours\n\nHaving previously participated in the same study\n\nImpaired skin integrity at the procedure site\n\nHaving a neurological or psychiatric diagnosis","6 Years","12 Years",{"count":56,"type":22},126,[25],"What is this study about, in short?\n\nThis study looks at simple, no-cost ways to reduce the pain and fear that children aged 6-12 feel when they have blood drawn at the hospital. Two methods are being tested:\n\n* A nurse lightly and rhythmically tapping with their fingertips just above the spot where the needle will go (\"rhythmic skin tapping\").\n* The child making an \"mmmm\" humming sound while the blood is being drawn (\"internal vibration\" or \"humming\").\n\nThese methods need no medicine and no device, so they can be used easily in any hospital. The study aims to find out whether these two methods really reduce pain and fear, by comparing them with a group that receives no extra method.\n\nWhy is this study being done? Drawing blood is one of the most common painful procedures in children. Fear of needles is very common and can even lead a person to avoid health care later in life. So it matters to make the blood-draw experience easier for children.\n\nSome methods used to reduce pain have practical limits:\n\n* Numbing creams must be applied 30-60 minutes before the procedure; they are not practical in urgent situations and add cost.\n* Special devices that give cold and vibration can work, but they can be expensive, are not always available, and need care for hygiene.\n\nFor these reasons, there is a need for simple methods that cost nothing, need no device, and can be applied easily in any setting. This study tests exactly that.\n\nHow do the methods work? (Simple science) Both methods rest on an idea called the \"Gate Control Theory\": in our body, the sense of touch and vibration competes with the sense of pain on the way to the brain. Gentle touch or mild vibration can act like a \"gate\" that partly blocks the pain signal from reaching the brain.\n\n* Rhythmic skin tapping: Gentle, rhythmic tapping with the fingers may help \"close the gate,\" so the pain is felt less.\n* Internal vibration (humming): The \"mmmm\" sound creates a mild vibration in the body. It can also stimulate the calming part of the nervous system, which may lower the heart rate and stress. Taking an active part in the procedure also gives the child a sense of control.\n\nWho can take part in the study?\n\nCan take part:\n\n* Children aged 6-12 years\n* Children who will have a blood draw\n* Children whose parent has given written permission and who themselves agree verbally\n* Children who can understand and speak Turkish\n* Children whose cognitive development is appropriate for their age\n* Children who do not have an ongoing (chronic) pain condition\n\nCannot take part, or will be withdrawn:\n\n* Children who do not want to take part, or wish to withdraw at any stage\n* Children who develop a complication (an unexpected medical problem) during the procedure\n* Children who have used a painkiller within the last 24 hours\n* Children who have already taken part in this study before\n* Children whose skin is broken at the site where the needle will go\n* Children who have a neurological or psychiatric diagnosis\n\nWhat will happen if my child takes part?\n\nThe blood draw will happen anyway because it is medically needed. The study only adds the method used during the draw and a short measurement afterward. Step by step:\n\n* Your child is placed by computer, at random (like drawing lots), into one of three groups. No one can choose the group in advance; this is called \"randomization\" and it keeps the comparison fair.\n* The blood draw is done as usual. The only difference is the method used, depending on your child's group.\n* Right after the procedure, the child is shown two short picture scales: one for pain, with faces ranging from smiling to crying (0-10), and one for fear, also made of faces (0-4).\n* A short form collects details such as age, sex, and any previous blood-draw experience.\n* No extra needle, medicine, or laboratory test is done beyond the routine blood draw.\n\nThe three groups are:\n\nGroup What is done in this group?\n\n1. Rhythmic skin tapping Gentle, rhythmic tapping with the fingertips just above the needle site.\n2. Internal vibration (humming) The child is asked to make an \"mmmm\" humming sound during the blood draw.\n3. Control group The blood draw is done as usual, with no extra method. This group is the comparison point used to measure the effect of the other two methods.\n\nWhere and when will the study take place?\n\n* Place: Kepez State Hospital Blood Collection Outpatient Clinic (Antalya, Türkiye).\n* Data collection period: June 2026 - June 2027. The total study duration is about 12 months.\n* Planned number of participants: 126 children in total (42 in each group). This number was set in advance by a statistical calculation so the results would be reliable.\n\nTaking part is completely voluntary\n\n* Your child does not have to take part. Even if you agree, you may withdraw at any time without giving a reason.\n* Not taking part, or withdrawing, will not affect the health care your child receives in any way.\n* Your child may also say they do not want the method; the child's decision is",[60,28,61,62,63,64],"Procedural Pain","Needle-Related Pain and Distress","Fear","Anxiety","Phlebotomy","RECRUITING","2026-08-18",{"date":68,"type":37},"2026-08-19",{"date":70,"type":37},"2026-07-01",{"date":72,"type":22},"2027-06",{"name":74,"class":75},"Akdeniz University","OTHER",{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100649779","transverse-vs-longitudinal-serratus-anterior-plane-block-in-breast-surgery-100649779","NCT07739277","Transverse vs. Longitudinal Serratus Anterior Plane Block in Breast Surgery","Efficacy of Transverse Versus Longitudinal Ultrasound Probe Orientation for Serratus Anterior Plane Block on Postoperative Pain in Breast Surgery: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged between 18 and 65 years\n* American Society of Anesthesiologists (ASA) physical status I, II, or III\n* BMI between 18 - 30 kg\u002Fm2\n* Patients scheduled for elective breast surgery\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy to local anesthetics\n* Infection at the injection site\n* Severe coagulopathy or use of anticoagulants\n* Chronic opioid use or history of neuropathic pain","65 Years",{"count":85,"type":22},70,[25],"The aim of this prospective, randomized controlled trial is to compare the analgesic efficacy of transverse versus longitudinal ultrasound probe orientations during Serratus Anterior Plane (SAP) block in patients undergoing breast surgery. The study hypothesizes that the longitudinal approach (probe parallel to the ribs) may provide better craniocaudal spread of the local anesthetic, thereby resulting in lower postoperative Visual Analog Scale (VAS) scores and reduced opioid consumption compared to the standard transverse approach.",[89,90,91,28,92],"Fascial Plane Block","Pain, Postoperative","Breast Surgery","Mastectomy",[94,95,96,91],"Serratus Anterior Plane Block","Regional Anesthesia","Postoperative Analgesia","2026-08-06",{"date":99,"type":37},"2026-08-07",{"date":97,"type":37},{"date":102,"type":22},"2027-02-19",{"name":104,"class":105},"Ankara Etlik City Hospital","OTHER_GOV",{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":114,"minAge":19,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":127,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":45},"100649711","analgesic-efficacy-of-combined-pecs-ii-and-pip-block-versus-thoracic-paravertebral-block-post-mastectomy-100649711","NCT07738770","Analgesic Efficacy of Combined PECS II and PIP Block Versus Thoracic Paravertebral Block Post-Mastectomy","Analgesic Efficacy Comparison of Combined PECS II and Superficial Parasternal Intercostal Plane (PIP) Block Versus Thoracic Paravertebral Block Post-Mastectomy: An Assessment of Pain Severity, Analgesia Duration, and Recovery Quality","PECS-TPVB","Inclusion Criteria:\n\n1. Female patients aged 18 to 60 years.\n2. Scheduled for breast cancer surgery (mastectomy with or without axillary lymph node dissection \\[ALND\\]).\n3. American Society of Anesthesiologists (ASA) physical status I to III.\n4. Provided signed written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Patient refusal to participate in the study.\n2. Known allergy to local anesthetics or study medications (e.g., bupivacaine, ketorolac, morphine).\n3. Coagulation disorders or coagulopathy.\n4. Mastectomy procedure with immediate breast reconstruction.\n5. Pre-existing chronic cancer pain with active usage of strong opioids (e.g., morphine, fentanyl).\n6. Cognitive impairment or inability to comprehend the pain assessment scale (NRS).\n7. Pregnancy.\n8. Active infection at the planned regional block injection site.","FEMALE","60 Years",{"count":117,"type":22},72,[25],"Postoperative pain management is crucial for patients undergoing mastectomy for breast cancer. Regional analgesia techniques, such as the Thoracic Paravertebral Block (TPVB), are commonly used to reduce pain and opioid consumption; however, TPVB carries potential risks, including pneumothorax. Interfascial plane blocks, specifically the Pectoral Nerve II (PECS II) block combined with the Superficial Parasternal Intercostal Plane (PIP) block, have emerged as alternative techniques to provide comprehensive analgesia to both the lateral and anterior chest wall.\n\nThe purpose of this randomized controlled trial is to evaluate and compare the analgesic efficacy and quality of postoperative recovery between a combination of ultrasound-guided PECS II and PIP blocks versus the standard Thoracic Paravertebral Block (TPVB) in patients undergoing mastectomy with or without axillary lymph node dissection (ALND).\n\nParticipants will be randomly assigned to receive either the combined PECS II and PIP block or the TPVB following general anesthesia induction. Pain scores, total opioid consumption, time to first analgesic request, quality of recovery using the QoR-15 questionnaire, and potential block-related complications will be monitored and compared over the 24-hour postoperative period.",[28,121,122,123,92,124,125,126],"Post Operative Analgesia","Post Operative Pain, Acute","Breast Cancer","Regional Anaesthesia","Analgesia Duration","Quality of Recovery (QoR-15)",[128,129,130,131,92,123,96,132],"Pectoral Nerve Block","PECS II Block","Parasternal Intercostal Plane Block","Thoracic Paravertebral Block","Quality of Recovery","2026-07-28",{"date":135,"type":37},"2026-07-31",{"date":137,"type":37},"2026-06-29",{"date":139,"type":22},"2026-12-31",{"name":141,"class":105},"Dharmais National Cancer Center Hospital",{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":148,"targetDuration":150,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":45},"100648117","building-a-swiss-pain-registry-a-national-framework-for-acute-and-chronic-pain-assessment-100648117","NCT07717762","Building a Swiss Pain Registry: A National Framework for Acute and Chronic Pain Assessment","Inclusion Criteria:\n\n* Signed informed consent by the participant or legal guardian for minors.\n* Diagnosis of acute or chronic pain (chronic pain defined as pain lasting ≥ 3 months), including nociceptive, neuropathic, or mixed pain conditions.\n* Referral for interdisciplinary outpatient pain assessment or treatment.\n* Sufficient proficiency in German, French, Italian, or English to complete digital assessments (parental proxy allowed for paediatric participants if needed).\n* All age groups included.\n\nExclusion Criteria:\n\n* Lack of capacity to provide informed consent or absence of a legal guardian for minors.\n* Inability to understand study languages and complete assessments even with assistance.\n* Acute life-threatening conditions precluding participation.\n* Site-specific safety considerations as determined by treating clinician.",{"count":149,"type":22},500,"24 Months","OBSERVATIONAL","The goal of this observational registry is to systematically collect and analyse real-world clinical and patient-reported data in individuals receiving treatment for acute and chronic pain. The main questions it aims to answer are: How do pain intensity, functional status, and quality of life evolve over time in patients with acute and chronic pain? How are different routine clinical treatment approaches associated with patient-reported outcomes in real-world clinical practice? Participants already receiving standard care for pain management will have routine clinical data recorded as part of their treatment and will be asked to complete standardized questionnaires on pain intensity, functional status, and quality of life at multiple time points during treatment and follow-up. Data are collected using a secure electronic system and are pseudonymised prior to analysis in accordance with Swiss data protection regulations.",[154,28],"Chronic Pain","2026-07-16",{"date":157,"type":37},"2026-07-21",{"date":159,"type":22},"2026-07-15",{"date":161,"type":22},"2029-08-15",{"name":163,"class":75},"Insel Gruppe AG, University Hospital Bern",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":45},"100636186","dose-response-effects-of-a-brief-audio-guided-mindfulness-intervention-for-acute-pain-100636186","NCT07562412","Dose-Response Effects of a Brief Audio-Guided Mindfulness Intervention for Acute Pain","Dose-Response Effects of a Brief Audio-Guided Mindfulness Intervention for Acute Pain While Awaiting Orthopedic Care","Inclusion Criteria:\n\n* Receiving treatment at Tallahassee Orthopedic Center\n* Understanding English instructions fluently\n* Being 18 years of age or older\n\nExclusion Criteria:\n\n* Unable to consent because of physical or mental incapacity.",{"count":172,"type":22},300,[25],"This project is a single-site, three-arm, randomized controlled trial investigating whether different length audio-recorded mindfulness practices differentially decrease pain among patients in a waiting room awaiting orthopedic care.",[176,177,178,179,28,154],"Pain","Pain Management","Mindfulness","Orthopedic","2026-07-10",{"date":182,"type":37},"2026-07-13",{"date":184,"type":37},"2026-04-29",{"date":186,"type":22},"2027-04-30",{"name":188,"class":75},"Florida State University",{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":199,"conditions":200,"keywords":204,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":45},"100645688","block-trauma-study-100645688","NCT07702071","BLOCK-TRAUMA Study","Regional Anesthesia Burden and Clinical Outcomes in Polytrauma Patients: A Prospective Cohort Study","BLOCK-TRAUMA","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosis of polytrauma, defined as traumatic injuries involving two or more anatomical regions.\n* Injury Severity Score (ISS) ≥16.\n* Hospital admission within 48 hours after injury.\n* Requirement for acute pain management during hospital treatment.\n* Receipt of at least one ultrasound-guided peripheral nerve block and\u002For continuous peripheral nerve catheter as part of routine clinical care.\n* Ability to collect clinical data on regional anesthesia procedures, analgesic use, pain assessment, and early recovery outcomes.\n* Written informed consent provided by the patient or legally authorized representative, according to local regulations.\n\nExclusion Criteria:\n\n* Age younger than 18 years.\n* Isolated single-system injury without polytrauma. ISS \\\u003C16.\n* Expected survival less than 24 hours after admission.\n* Severe traumatic brain injury or impaired consciousness preventing reliable pain and functional assessment, unless validated behavioral pain scales can be used.\n* Known allergy or contraindication to local anesthetics.\n* Pre-existing severe neuromuscular disease affecting motor function assessment.\n* Chronic opioid therapy before injury.\n* Pregnancy.\n* Enrollment in another interventional trial that may affect pain management or functional recovery outcomes.\n* Missing essential data required for assessment of Regional Anesthesia Burden.","50 Years",{"count":149,"type":22},"This prospective cohort study will evaluate the association between the overall burden of regional anesthesia and early clinical outcomes in adult patients with polytrauma.\n\nPatients with severe trauma often experience pain from multiple injury sites and may require more than one peripheral nerve block or continuous regional anesthesia catheter. While regional anesthesia can improve pain control and reduce opioid use, multiple blocks and catheters may also increase treatment complexity, local anesthetic exposure, motor weakness, and monitoring challenges.\n\nThe study will prospectively collect data on the number and type of regional anesthesia procedures, local anesthetic exposure, catheter use, pain intensity, opioid consumption, mobility, complications, and early recovery outcomes. The goal is to determine whether increasing regional anesthesia burden is associated with improved analgesia, functional recovery, or increased risk in polytrauma patients.",[201,124,202,28,203],"Polytrauma","Nerve Block","Combat Trauma",[201,95,205,28,206,207],"Peripheral Nerve Block","Local Anesthetics","Combat Injury","2026-07-09",{"date":210,"type":37},"2026-07-14",{"date":212,"type":22},"2026-07-23",{"date":214,"type":22},"2026-10-23",{"name":216,"class":75},"Ukrainian Society of Regional Anesthesia and Pain Therapy",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":224,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":243},"100483781","rebooting-infant-pain-care-using-machine-learning-and-skin-to-skin-contact-to-exponentially-improve-neonatal-intensive-care-unit-practice-100483781","NCT05579496","Rebooting Infant Pain Care: Using Machine Learning and Skin-to-Skin Contact to Exponentially Improve Neonatal Intensive Care Unit Practice","BabyAIBabyCalm","QUALITATIVE INTERVIEWS\n\nInclusion Criteria:\n\n* Parents of a child currently in the NICU or\n* Health professionals currently working in the NICU.\n\nExclusion Criteria:\n\n\\*Participants who cannot communicate fluently in English\n\nQUANTITITATIVE DATA CAPTURE (video, eeg, ecg, RR, SPo2)\n\nInclusion Criteria:\n\n* Infants born between 25 0\u002F7 weeks 32 6\u002F7 weeks gestational age\n* Infants who are within 8 weeks postnatal age\n* Infants who are undergoing a routine heel lance\n\nExclusion Criteria:\n\n* Infants with congenital malformations\n* Infants receiving analgesics or sedatives at the time of study (aside from sucrose)\n* Infants with history of perinatal hypoxia\u002Fischemia at the time of study\n* Infants with diaper rash or excoriated buttocks\n* Parents who are not fluent in English","25 Weeks","33 Weeks",{"count":227,"type":22},400,"To address the current limitations related to infant pain assessment in the NICU, our international team of knowledge users and health\u002Fnatural science\u002Fengineering\u002Fsocial science researchers have come together to build a machine learning algorithm that will learn how to discriminate invasive and non-invasive distress. Furthermore, to improve the use of current pain management practices, our team seeks to better understand the developmental mechanisms underlying skin-to-skin contact over time and factors that may influence its efficacy in mitigating pain responses in preterm infants. This is an ongoing naturalistic observational study.",[28],[231,232,233,234,235,177],"NICU (Neonatal Intensive Care Unit)","Artificial Intelligence","Pain Assessment","Skin-to-Skin Contact","Parent Stress",{"date":182,"type":37},{"date":238,"type":37},"2020-11-01",{"date":240,"type":22},"2031-03",{"name":242,"class":75},"York University",2,{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":17,"sex":18,"minAge":251,"maxAge":115,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":243},"100645959","ketamine-versus-dexmedetomidine-as-an-adjuvant-in-scalp-block-in-supratentorial-brain-tumor-excision-surgeries-100645959","NCT07698665","Ketamine Versus Dexmedetomidine as an Adjuvant in Scalp Block in Supratentorial Brain Tumor Excision Surgeries","Efficacy of Ketamine Versus Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block in Adults Undergoing Supratentorial Brain Tumor Excision Surgeries for Hemodynamics and Pain Control, Double-blinded Randomized Study","Inclusion Criteria:\n\n* Age from 20 to 60 years, both sexes, American Society of Anesthesiologists (ASA) physical status II-III, Supratentorial tumor excision, Supine Position.\n\nand operation time: less than 6 hours.\n\nExclusion Criteria:\n\n* Patient refusal, disturbed consciousness level (Glasgow Coma Scale \\[GCS\\] \\\u003C 15). Patients who required reintubation during the study period, those not extubated. immediately after surgery, or those who awoke with neurological deficits impairing. pain assessments were excluded from the final analysis, history of psychotic disorders or previous surgeries, Poor cognitive function.\n\nPostictal state or uncontrolled\u002Frecurrent seizures, known allergy to dexmedetomidine or ketamine, difficult intubation (Mallampati score \\> III) or multiple intubation attempts, operation duration \\> 6 hours, renal dysfunction (creatinine \\> 1.2 mg\u002FdL, BUN \\> 20 mg\u002FdL), heart block and patients with chronic headache disorders or those receiving chronic analgesic therapy (for \\>3 months) were excluded.","20 Years",{"count":253,"type":22},90,[25],"Supratentorial brain tumor surgeries are associated with significant nociceptive stimulation and postoperative pain, which may adversely affect patient outcomes. Scalp block has emerged as an effective regional anesthetic technique to improve analgesia and reduce opioid consumption.\n\nObjective: To compare efficacy of ketamine versus dexmedetomidine as adjuvants to bupivacaine in scalp blocks for supratentorial brain tumor surgeries, focusing on analgesia, opioid consumption, and hemodynamic stability.\n\nMethods:\n\nThis randomized double-blinded controlled trial included 80 patients undergoing supratentorial tumor excision, allocated equally into two groups: Group K received bupivacaine with ketamine (2 mg\u002Fkg), and Group D received bupivacaine with dexmedetomidine (1 µg\u002Fkg). Intraoperative hemodynamics, fentanyl consumption, postoperative pain scores (NRS), analgesic requirements, and complications were assessed.",[257,258,28],"Regional Anesthesia Morbidity","Supratentorial Brain Tumor",[260,261,262],"Scalp block","Dexemetomedine","Supratentorial","2026-07-07",{"date":182,"type":37},{"date":266,"type":37},"2026-01-01",{"date":268,"type":22},"2026-07-30",{"name":270,"class":75},"Cairo University",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":282,"conditions":283,"keywords":286,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":4},"100636486","phase-4-study-of-ql-analgesic-response-and-extent-100636486","NCT07566312","Study of QL Analgesic Response and Extent","Anterior Versus Posterior Versus Lateral Quadratus Lumborum Block: a Randomized Control Trial in Healthy Volunteers","SQUARE","Inclusion Criteria:\n\n* Ability to provide written informed consent\n* Ability and willingness to comply with the study procedures and duration requirements\n* ASA physical status 1 or 2\n* Age ≥ 18 years\n* Weight \\> 70kg\n\nExclusion Criteria:\n\n* BMI \\> 35kg.m2\n* Use of analgesics within 24 hours before the procedure\n* History of thoracic trauma or surgery\n* Abdominal deformities or abnormalities that may prevent proper block performance\n* Abdominal tattoos in the area of block performance\n* Systemic neuromuscular disease\n* Contraindications to regional anesthesia (e.g., infection, allergy, challenging sonoanatomy)\n* Structures are unable to be visualized by ultrasound\n* Pregnancy\n* Other known health conditions that would affect the participant's ability to successfully complete the study",{"count":7,"type":22},[281],"PHASE4","A total of 14-18 healthy volunteers will be included. There will be three different procedure days, separated by at least one week. On each visit, the subjects will receive a QL block, according to the randomization process. Each volunteer will undergo pre-procedure screening on the first visit. The blocks will be performed on the same side, by the same anesthesiologist, with at least one week between each block. An anterior QL block will be administered on one day, a posterior QL block on another, and a lateral QL block on the third. The order will be randomized, and both the subject and the research team member assessing the block will be blinded. To compare the dermatomal sensory block distribution, the investigators will use detailed mapping with pinprick, cold, and heat stimuli. A handheld dynamometric assessment of lower extremity strength. The testing will be performed 60 to 90 minutes after performance of the blocks.",[28,284,285],"Postoperative Pain","Regional Anesthesia Block",[287,288,289,290,291,292,293],"Quadratus lumborum block","QL block","QL","Quadratus lumborum","Fascial plane block","Regional anesthesia","Abdominal blocks",{"date":295,"type":37},"2026-07-08",{"date":297,"type":22},"2027-01",{"date":299,"type":22},"2027-04",{"name":301,"class":75},"Duke University",{"id":303,"slug":304,"hasResults":17,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":328,"locationsCount":45},"100320027","phase-1-vasopressin-and-pain-perception-in-the-brain-100320027","NCT03446456","Vasopressin and Pain Perception in the Brain","The Influence of Vasopressin on Observational Learning of Placebo Analgesia","Inclusion Criteria:\n\n* Age ( 18-55 years old)\n* English speaker (written and spoken)\n\nExclusion Criteria:\n\n* Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, degenerative neuromuscular disease, history of cancer within past 3 years\n* Any history of chronic pain disorder or currently in pain\n* Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, mania, autism) and \u002For psychiatric condition leading to treatment and\u002For hospitalization within the last 3 years.\n* Family (first degree) history of mania, schizophrenia, or other psychoses\n* Lifetime alcohol\u002Fdrug dependence or alcohol\u002Fdrug abuse in past 3 months\n* Pregnancy or breast feeding\n* Color-blindness\n* Impaired, uncorrected hearing\n* History of angioedema\n* High blood pressure (above 140 mmHg) or symptomatic low blood pressure\n* History of fainting\n* Left handed\n* Allergies or sensitivities to creams, lotions or food coloring\n* Any non-organic implant or any non-removable metal device (e.g. pacemaker, cochlear implants, stents, surgical clips, non-removable piercings)\n* Any prior eye injury or the potential of a foreign body in the eye (e.g. worked in metal fields)Persisting functional impairment due to a head trauma\n* Fear of closed spaces\n* Any other contraindications for MRI (e.g. large tattoos on head and neck)\n* Previously participated in a \"Pain Perception in the Brain\" Study\n* Failed drug test (testing for opiates, cocaine, methamphetamines, amphetamines and THC)",{"count":310,"type":22},56,[312,313],"PHASE1","PHASE2","The feeling of pain is not just a sensory experience, but is also influenced by emotions, beliefs and expectations, making pain a highly subjective experience. This is evident in clinical practice, where the behavior of the physician and the treatment context can strongly influence the pain experience of patients. Research has shown that patients' expectation that a treatment will reduce pain influences individual perception of pain, even if the treatment has no active ingredient. The expectancy-induced analgesia emerges due to a modulation of the individual pain experience of patients by an engagement of endogenous inhibitory systems in the central nervous system.\n\nThe development of expectancy-induced analgesia can be generated in several ways. The investigators have previously demonstrated that social information and observational learning (e.g. the patient observes analgesia in another person receiving a treatment) can lead to expectancy-induced analgesia and pain reduction. However, the neural mechanisms (mechanisms in the brain) of how these expectancies are acquired and the neural mechanisms of analgesia induced by observational learning are unknown.\n\nThe investigators recently established a procedure to investigate neural mechanisms of observational learning in placebo analgesia. Here the investigators propose to investigate the influence of vasopressin, a neurotransmitter that is important for social interaction, on observational learning.\n\nThe investigators will use functional magnetic resonance imaging (fMRI), a non-invasive method, to investigate neural activity in humans. Participants will either receive vasopressin or saline with a nasal spray. During fMRI scanning, participants will then undergo an observational learning phase, where the study participants will learn the experience of analgesia in another person through a video, and a testing phase, where participants will perceive painful stimulations with the same cues as the observational phase. The comparison of the vasopressin group and the saline group will allow us to investigate how vasopressin influences behavioral effects of observational learning on pain perception as well as its effect on the neural processing of observational learning.\n\nA better understanding of how the human brain processes observationally-induced analgesia would allow us to improve the therapeutic context of pain treatments by increasing the contextual factors which help patients cope with pain.",[28],[317,318,319,320,321,322],"Magnetic Resonance Imaging","Healthy Volunteers","Arginine Vasopressin","Antidiuretic Hormone","Analgesia","Social Behavior","2026-07-06",{"date":208,"type":37},{"date":326,"type":37},"2018-09-17",{"date":139,"type":22},{"name":329,"class":75},"University of Maryland, Baltimore",{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100646279","postoperative-outcomes-of-regional-blocks-in-cervical-disc-surgery-100646279","NCT07694180","Postoperative Outcomes of Regional Blocks in Cervical Disc Surgery","Postoperative Outcomes of Regional Blocks Performed in Cervical Disc Surgery: A Prospective Observational Study","Inclusion Criteria:\n\n* Patients aged between 18 and 70 years.\n* American Society of Anesthesiologists (ASA) physical status I, II, or III.\n* Patients scheduled for elective anterior cervical discectomy and fusion (ACDF) surgery under general anesthesia.\n* Patients who provide written informed consent and agree to participate in the study.\n\nExclusion Criteria:\n\n* Patients with a history of bleeding diathesis or those receiving anticoagulant therapy.\n* Patients with a known allergy or hypersensitivity to local anesthetics or opioid medications.\n* Patients with infection at the planned block site.\n* Patients with a history of previous cervical spine surgery.\n* Patients with a history of gabapentinoid or corticosteroid use within the last 3 weeks.","70 Years",{"count":339,"type":22},66,"The aim of this study is to evaluate the postoperative analgesic efficacy of the Serratus Posterior Superior Intercostal Plane Block (SPSIP block) in patients undergoing Anterior Cervical Discectomy and Fusion (ACDF) surgery and to compare the outcomes with those of patients who do not receive regional anesthesia.",[28,342],"Servical Disc Herniation","2026-07-02",{"date":208,"type":37},{"date":346,"type":22},"2026-06-22",{"date":348,"type":22},"2027-01-02",{"name":350,"class":75},"Samsun University",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":362,"briefSummary":363,"conditions":364,"keywords":367,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":45},"100615344","effectiveness-of-retrolaminar-block-in-lumbar-spine-fusion-with-multimodal-analgesia-100615344","NCT07291388","Effectiveness of Retrolaminar Block in Lumbar Spine Fusion With Multimodal Analgesia","Effectiveness of Retrolaminar Block in Reducing Postoperative Opioid Consumption in Patients Undergoing Lumbar Spine Fusion With Multimodal Analgesia","RBLUF","Inclusion Criteria:\n\n* Adults aged 18-75 years, scheduled for lumbar spine fusion surgery by a trauma team\n* American Society of Anesthesiologists (ASA) Classification I-III\n* Willing and able to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* History of chronic use of strong or weak opioids for more than 3 months.\n* Diagnosis of chronic pain and treatment by a pain management team.\n* ASA score greater than or equal to 4.\n* Patients with prior lumbar spine surgery. Spinal instrumentation at the surgical site.\n* Estimated creatinine clearance less than 60 ml\u002Fmin.\n* Coagulation disorder or abnormal coagulation tests.\n* Infection at the surgical site.\n* Weight less than 50 kg.\n* Altered mental status that prevents reliable evaluation.\n* Allergy to local anesthetics or analgesic drugs used in the study.\n* Patients with contraindications to peripheral nerve blocks.\n* Lumbar spine fixation due to oncologic disease or acute trauma.\n* Use of intraoperative neuromonitoring and TIVA.","75 Years",{"count":361,"type":22},44,[25],"This randomized, blinded, controlled clinical trial aims to evaluate the effectiveness of ultrasound-guided retrolaminar block in reducing postoperative opioid consumption in patients undergoing lumbar spine fusion surgery under multimodal analgesia.\n\nThe participants will:\n\n* Be randomly assigned in a 1:1 ratio to receive either a retrolaminar block with 0.25% bupivacaine plus epinephrine or a sham block (normal saline) prior to surgical incision.\n* Receive standardized multimodal analgesia.\n* Have follow-up by the Acute Pain Unit during the first 3 days, to assess opioid consumption (morphine) in 24 hours, pain intensity measured by Numeric Rating Scale, quality of recovery assessed by the QoR-15 questionnaire, intraoperative blood loss, and postoperative complications.",[28,365,366],"Anesthesia","Lumbar Spine Disease",[368,369,370,371],"acute pain","retrolaminar block","regional anesthesia","lumbar arthrodesis",{"date":323,"type":37},{"date":374,"type":37},"2026-06-30",{"date":376,"type":22},"2027-03",{"name":378,"class":75},"Pontificia Universidad Catolica de Chile",{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":18,"minAge":386,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":389,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":397,"locationsCount":45},"100610288","phase-3-a-study-of-combogesic-iv-intravenous-in-pediatric-patients-with-acute-pain-100610288","NCT07225634","A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain","An Open Label, Pharmacokinetic and Safety Study of Combogesic® IV in Pediatric Patients With Acute Pain","Inclusion Criteria:\n\n1. Is male or female aged between 2 and \\\u003C17 years.\n2. Have a clinical indication of acute pain\\* requiring hospitalization and multiple doses of parenterally administered nonopioid analgesic medication for at least 0.5 - 5 days.\n3. Is either able to provide written informed consent or consent is provided from parents\u002Flegal guardians and assent provided from participants (where appropriate).\n4. Is willing and able to remain at the study site for at least 12 hours and to attend a follow-up visit at 7 ± 2 days after the last dose of study drug.\n5. Have negative HIV and hepatitis B \\& C test results.\n\n   * Acute pain indications may include but are not limited to post-operative pain associated with musculoskeletal or soft tissue surgery, fractures or injury, or medical procedures.\n\nExclusion Criteria:\n\n1. Has a known history of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, opioids, or any nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen); history of NSAID-induced bronchospasm (subjects with the triad of asthma, nasal polyps, and chronic rhinitis are at greater risk for bronchospasm and should be considered carefully); or hypersensitivity, allergy, or significant reaction to sulfa (including sulfonamide) medicines, ingredients of the study drug, or any other drugs used in the study including anesthetics and antibiotics that may be required.\n2. Has experienced any surgical complications or other issues that, in the opinion of the Investigator, could compromise the safety of the subject if he or she participates in the study or could confound the results of the study.\n3. Has any clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease or any other condition that, in the opinion of the Investigator, could compromise the subject's welfare, ability to communicate with the study staff, or otherwise contraindicate study participation.\n4. Has a history or current diagnosis of a significant psychiatric disorder that, in the opinion of the Investigator, would affect the subject's ability to comply with the study requirements.\n5. Has a history of a clinically significant (Investigator opinion) gastrointestinal (GI) event within 6 months before screening or has any history of peptic or gastric ulcers or GI bleeding.\n6. Has a surgical or medical condition of the GI or renal system that might significantly alter the absorption, distribution, or excretion of any drug substance.\n7. Is considered by the Investigator, for any reason to be an unsuitable candidate to receive the study drug.\n8. Is receiving systemic chemotherapy, has an active malignancy of any type, or has been diagnosed with cancer within 5 years before Screening (excluding treated squamous or basal cell carcinoma of the skin).\n9. Is currently receiving anticoagulants (e.g. heparin or warfarin).\n10. Has received a course of systemic corticosteroids (either oral or parenteral) within 3 months before screening (inhaled nasal steroids and regional\u002Flimited area application of topical corticosteroids (Investigator discretion) are allowed).\n11. Has a history of chronic use (defined as daily use for \\> 2 weeks) of NSAIDs, opiates, or glucocorticoids (except inhaled nasal steroids and regional\u002Flimited topical corticosteroids), for any condition within 6 months before study drug administration. Aspirin at a daily dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the subject has been on a stable dose regimen for ≥ 30 days before screening and has not experienced any relevant medical problem.\n12. Has a significant renal or hepatic disease, as indicated by clinical laboratory assessment (results ≥ 3 times the upper limit of normal \\[ULN\\] for any liver function test, including aspartate aminotransferase \\[AST\\], alanine aminotransferase \\[ALT\\], or creatinine ≥ 1.5 times the ULN).\n13. Has any clinically significant laboratory finding at screening that, in the opinion of the Investigator, contraindicates study participation.\n14. Participated in another clinical study within 30 days before Screening.\n15. Pregnant or lactating females\n16. Sexually active females of childbearing potential not using adequate contraception and sexually active males not using adequate contraception","2 Years","16 Years",{"count":5,"type":22},[390],"PHASE3","Combogesic® IV is an intravenous medicine (given by vein) containing a combination of two pain relief (analgesic) medicines called ibuprofen and acetaminophen. The goal of this clinical trial is to study the way that the body processes and clears the intravenous infusion of Combogesic® IV and that it is safe to be used in children and adolescents between the ages of 2 and \\\u003C17 years.\n\nWhat will the study involve for participants?\n\n* Combogesic® IV will be administered every 6 hours as necessary with a maximum of 4 doses within a 24-hour period as an intravenous infusion for about 15 minutes.\n* Participants will receive Combogesic® IV for a minimum of 12 hours (2 doses) up to a maximum of 5 days (20 doses). Dosing will be dependent on body weight.\n* If pain is not sufficiently controlled by Combogesic® IV, opioids may be used as supplementary pain relief at the discretion of the study doctor.\n* Have their blood samples collected before dosing and at specific times after dosing. The amount of study drug in the blood will be measured, and safety assessments (including blood and urine samples) will be done.\n* Rate the study drug at the end of the treatment.\n\nIt is expected that Combogesic® IV will be well tolerated in children and adolescents and that the pharmacokinetics findings will be similar as compared with adults.",[28],{"date":70,"type":37},{"date":395,"type":22},"2026-09",{"date":299,"type":22},{"name":398,"class":399},"AFT Pharmaceuticals, Ltd.","INDUSTRY",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":359,"enrollmentInfo":407,"targetDuration":4,"studyType":23,"phases":409,"briefSummary":410,"conditions":411,"keywords":414,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":422,"leadSponsor":424,"locationsCount":45},"100646953","qipb-vs-si-ficb-for-postoperative-analgesia-after-total-hip-arthroplasty-100646953","NCT07683663","QIPB vs SI-FICB for Postoperative Analgesia After Total Hip Arthroplasty","Comparison of Quadro-Iliac Plane Block and Supra-Inguinal Fascia Iliaca Compartment Block for Postoperative Analgesia in Total Hip Arthroplasty: A Prospective, Double-Blind, Non-Inferiority Study","Inclusion Criteria:\n\n* Adults aged 18-75 years\n* Scheduled for elective primary total hip arthroplasty\n* ASA physical status I-III\n* Able to understand and communicate in Turkish and complete assessment scales\n* Completed preoperative anesthesia evaluation and approved for surgery\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Known allergy\u002Fcontraindication to any local anesthetic, including bupivacaine\n* Coagulopathy or anticoagulant\u002Fantiplatelet therapy contraindicating block (per ASRA 2022)\n* Active infection or skin breakdown at the block site\n* Chronic opioid use (≥3 months daily) or history of opioid dependence\n* Morbid obesity (BMI \\> 40 kg\u002Fm²)\n* Cognitive impairment or communication difficulty precluding reliable NRS\u002FQoR-15 assessment\n* Pregnancy or breastfeeding\n* Revision THA or emergency THA for fracture\n* Intraoperative complications requiring major protocol deviation (e.g., \\>1000 mL blood loss, cardiac arrest)\n* Technically failed block (no sensory change at any region on the T1 cold test)",{"count":408,"type":22},84,[25],"Total hip arthroplasty (THA) causes moderate-to-severe postoperative pain. The PROSPECT guideline recommends the supra-inguinal fascia iliaca compartment block (SI-FICB) for THA, whereas evidence for newer quadratus-lumborum-family blocks is limited. The quadro-iliac plane block (QIPB) is a recently described fascial plane block, and no study has compared QIPB with SI-FICB head-to-head in any surgical context. In this prospective, double-blind, patients undergoing elective THA who receive one of the two routinely used preoperative blocks (SI-FICB or QIPB, chosen by the attending anesthesiologist as part of routine care) are systematically observed and compared. The primary objective is to assess whether the postoperative analgesic efficacy of QIPB is non-inferior to SI-FICB, using the resting NRS pain score at 6 hours postoperatively as the primary endpoint (non-inferiority margin Δ = 1.3).",[412,413,284,28],"Hip Osteoarthritis","Total Hip Arthroplasty (THA)",[370,415,416,417,418],"quadro-iliac plane block","fascia iliaca block","opioid consumption","quality of recovery","2026-06-27",{"date":323,"type":37},{"date":374,"type":22},{"date":423,"type":22},"2027-06-01",{"name":425,"class":75},"Dokuz Eylul University",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":438,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":45},"100430102","phase-2-twin-block-pain-medications-and-third-molar-extractions-100430102","NCT04880707","Twin Block, Pain Medications and Third Molar Extractions","Myogenous Face Pain Following Third Molar Extractions Under Intravenous Sedation","Inclusion Criteria:\n\n* All patients requiring extraction\u002Fs of at least 1 lower wisdom (third) molar that is partially\u002Ffully 'impacted', under intravenous sedation, are eligible to participate in this study so long as they\n\n  1. are older than 18 years of age,\n  2. are healthy,\n  3. have no cognitive\u002Fintellectual disability,\n  4. have no past\u002Frecent pain or reduced range of motion in their jaw joint\u002F muscle complex, no trauma or surgery in their jaw region.\n  5. have an electronic device such as a smart phone or a tablet\u002F computer with internet connection.\n  6. are willing to participate in the study and not be excluded by the following criteria below.\n\nExclusion Criteria:\n\n* Any patients, even if satisfying the criteria above, may not take part if they have any of the following:\n\n  1. Compromised ability to guard their self-interest, for e.g., prisoners, children, pregnant women, patients with intellectual\u002Fcognitive disability are not enrolled in the study.\n  2. Those patients who present with infection\u002Finflammation involving the third molars slated for extractions, on the day of their procedure, may not take part in the study.\n  3. In addition, those who have had opioid pain medication\u002Fs in the past to address short-term or long-standing pain, or those who are on long term prescription of anti-inflammatory pain medication, are unable to participate.\n  4. Those with long standing pain of the jaw joint or muscles.\n  5. Finally, those patients who are allergic to\u002Funable to tolerate either the dental local anesthetic or its components, opioids, acetaminophen ('Tylenol') or ibuprofen ('Motrin' or 'Advil') also may not take part in the study.",{"count":434,"type":22},48,[313],"Each year, over 3.5 million, mostly, healthy young adults, have their third molar teeth ('wisdom teeth') removed under sedation and are often given opioid prescriptions for managing their pain. Wisdom molar removal is one of the most common reasons for opioid prescriptions to be given to adolescents. There is a national thrust to reduce both the dose and the duration of such opioid prescriptions because even short-term opioid exposures increase risk for narcotic addiction and misuse. Non-opioid options to manage pain will still allow for sufficient pain control without risking addiction, and hence, a fundamental component of our response to combat the current national opioid crisis.\n\nThe investigators are going to study a promising option- the Twin Block dental anesthetic injection. The Twin block involves injecting the standard dental numbing medication in a way that 'numbs' the 'jaw-clencher' muscles on the side of the face. The investigators found that the Twin block relieved jaw pain stemming from these muscles, in a quick and sustained manner, even in patients whose pain following wisdom tooth removal primarily came from 'taut' and tender jaw-clencher muscles. However, what is not known is- how often do patients who have their wisdom teeth removed under sedation, end up in significant pain from taut and tender jaw-clencher muscles? Will using the twin block effectively reduce pain in such patients? In this pilot study, the investigators will examine wisdom molar extraction patients one day after their procedure. Those with significant pain (pain rated ≥ 5 on a 0-10 scale) in their jaw-clencher muscles, will get either the Twin block injection or a placebo. The investigators will track both 1) pain before and after the injection, and 2) pain medication usage over a 7-day period to see if both pain and opioid dosage come down with the Twin block. This study can support a simple, safe and inexpensive means to reduce pain after a common procedure.",[28],[439,440,441],"Twin block","Prescription opioids","Acute post-extraction pain","2026-06-17",{"date":346,"type":37},{"date":445,"type":37},"2024-03-11",{"date":447,"type":22},"2026-12",{"name":449,"class":75},"Rutgers, The State University of New Jersey",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":23,"phases":459,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":470,"leadSponsor":471,"locationsCount":4},"100598188","phase-2-rectus-sheath-trial-100598188","NCT07068243","REctus Sheath Trial","Transverse Versus Longitudinal Approaches for Rectus Sheath Block: a Randomized Controlled Trial in Healthy Volunteers","REST","Inclusion criteria:\n\n1. Ability to provide written informed consent\n2. Ability and willingness to comply with the study procedures and duration requirements\n3. ASA physical status 1 or 2\n4. Age ≥ 18 years\n5. Weight \\> 60kg\n\nExclusion criteria:\n\n1. BMI \\> 40kg.m-2\n2. Use of analgesics within 24 hours before the procedure\n3. History of abdominal trauma or surgery\n4. Abdominal deformities or abnormalities that may prevent proper block performance\n5. Abdominal tattoos in the supraumbilical area\n6. Systemic neuromuscular disease\n7. Contraindications to regional anesthesia (e.g., infection, allergy)\n8. Structures are unable to be visualized by ultrasound\n9. Pregnancy\n10. Other known health conditions that would affect the participant's ability to successfully complete the study",{"count":7,"type":22},[313],"Regional anesthesia techniques (or nerve blocks) are used to provide sensory blockade over the abdominal wall. The most established technique is thoracic epidural. This provides bilateral spread but is also associated with neuraxial complications, which has led to a decrease in clinical usage. The rectus sheath block (RSB) is an established regional anesthesia technique used to provide somatic analgesia to the midline anterior abdominal wall by depositing local anesthetic in the posterior rectus sheath, thereby targeting the terminal anterior branches of the lower thoracic intercostal nerves. The conventional approach involves placing the ultrasound (US) probe transversely across the rectus abdominis muscle and advancing the needle in-plane either lateral-to-medial or medial-to-lateral. While this technique achieves spread within the sheath, the cephalocaudal distribution of local anesthetic may be suboptimal, potentially limiting the extent of dermatomal coverage. A longitudinal probe orientation, with needle insertion from cephalad to caudad, may theoretically facilitate a more extensive cranio-caudal spread by aligning the injection axis with the anatomical fascial plane of the posterior rectus sheath. However, the relative efficacy of these two approaches has not been investigated in a controlled, comparative setting. Thus, this randomized, single-blinded trial aims to evaluate the dermatomal sensory distribution and ultrasound-assessed local anesthetic spread achieved by the transverse versus longitudinal in-plane approaches to ultrasound-guided RSB in healthy adult volunteers. To compare the dermatomal sensory block distribution, investigators will use dermatomal mapping with pinprick, and cold.",[28,462],"Postoperative Pain, Acute",[464,465,89,466],"Rectus Sheath Block","Abdominal Block","RSB","2026-06-16",{"date":442,"type":37},{"date":395,"type":22},{"date":299,"type":22},{"name":301,"class":75},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":479,"targetDuration":4,"studyType":23,"phases":481,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":489,"leadSponsor":491,"locationsCount":45},"100643831","phase-4-effect-of-liposomal-bupivacaine-on-rebound-pain-after-peripheral-nerve-block-in-orthopedic-surgery-100643831","NCT07606911","Effect of Liposomal Bupivacaine on Rebound Pain After Peripheral Nerve Block in Orthopedic Surgery.","Liposomal Bupivacaine Combined With Plain Bupivacaine for Peripheral Nerve Block to Reduce Rebound Pain After Orthopedic Extremity Surgery: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* 18-65 years old;\n* ASA Physical Status 1-3;\n* Scheduled for elective unilateral orthopedic surgery of the upper or lower extremity.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding;\n* Bupivacaine sensitivity or known allergy;\n* Contraindication for nerve blocks;\n* Enrollment in another clinical trial that could confound pain evaluation;\n* Other conditions that preclude study participation.",{"count":480,"type":22},668,[281],"This study will prospectively compare the preventive effect of liposomal bupivacaine combined with plain bupivacaine versus plain bupivacaine alone on rebound pain after nerve block in patients undergoing orthopedic extremity surgery. The primary aim is to assess whether the combination reduces the incidence or severity of rebound pain (i.e., more effectively covers the postoperative inflammatory peak on days 2-3 and provides a smoother regression curve of sensory blockade). Secondary aims include evaluation of upper limb functional scores, occurrence of chronic pain, and health-related quality of life. All aims will be assessed over 72 hours or the duration of hospitalization if shorter.",[28,484],"Orthopaedic Surgery","2026-06-07",{"date":487,"type":37},"2026-06-09",{"date":70,"type":22},{"date":490,"type":22},"2027-12-01",{"name":492,"class":75},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital",{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":500,"enrollmentInfo":501,"targetDuration":4,"studyType":23,"phases":503,"briefSummary":504,"conditions":505,"keywords":509,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":45},"100643654","comparison-of-iv-analgesia-protocols-after-the-regional-blocks-effect-diminishes-in-thoracic-surgery-100643654","NCT07610408","Comparison of IV Analgesia Protocols After the Regional Block's Effect Diminishes in Thoracic Surgery","Comparison of the Effectiveness of Intravenous Analgesia Protocols Used After the Duration of Block Action for Postoperative Pain Control in Thoracic Surgery","Inclusion Criteria:\n\n1. \\- Patients aged 18 to 80 years.\n2. \\- ASA (American Society of Anesthesiologists) Physical Status Score of I-III.\n3. \\- Body Mass Index (BMI) between 18 and 35 kg\u002Fm².\n4. \\- Undergoing elective thoracic surgery via Video-Assisted Thoracoscopic Surgery (VATS).\n5. \\- Voluntary participation confirmed by signing the written Informed Consent Form.\n\nExclusion Criteria:\n\n1. \\- Age below 18 or above 80 years.\n2. \\- Advanced organ failure (e.g., severe hepatic or renal impairment).\n3. \\- ASA physical status \\> III.\n4. \\- History of chronic pain treatment or long-term opioid use.\n5. \\- BMI \\\u003C 18 kg\u002Fm² or \\> 35 kg\u002Fm².\n6. \\- Pregnancy or breastfeeding.\n7. \\- Limited cooperation due to dementia or uncontrolled psychiatric disorders.\n8. \\- Communication barriers (inability to communicate in the native language).\n9. \\- History of substance or drug abuse.\n10. \\- Known allergy or contraindication to the study drugs (Fentanyl, Tramadol, or Ibuprofen).\n11. \\- Contraindication to regional block placement (e.g., infection at the injection site).","80 Years",{"count":502,"type":22},135,[25],"The purpose of this study is to compare the effectiveness of three different intravenous (IV) patient-controlled analgesia (PCA) regimens-Fentanyl, Tramadol, and Ibuprofen-in managing postoperative pain and respiratory performance in patients undergoing Video-Assisted Thoracoscopic Surgery (VATS). While regional blocks like Erector Spinae Plane (ESP) block provide effective early analgesia, their effect typically diminishes after 8-12 hours, leading to potential 'rebound pain.' This study specifically investigates the period following the duration of the regional block's action. The primary goal is to evaluate which IV PCA protocol better controls pain (Visual Analog Scale scores) and supports better respiratory performance (measured by incentive spirometry) during the first 72 hours post-surgery",[506,284,507,508,28],"Postoperative Pain After Thoracic Surgery","Thoracic Surgery, Video Assisted","Patient Controlled Analgesia",[510,511,512,513,514,515,516,517,518,519,520],"Video-Assisted Thoracoscopic Surgery","VATS","Erector Spinae Plane Block","ESP","Patient-Controlled Analgesia","PCA","IV analgesia","Incentive spirometry","Opioid-sparing","Postoperative pain after thoracic surgery","Rebound Pain","2026-06-06",{"date":487,"type":37},{"date":524,"type":37},"2026-06-02",{"date":526,"type":22},"2026-10-15",{"name":104,"class":105},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":535,"targetDuration":4,"studyType":23,"phases":537,"briefSummary":538,"conditions":539,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":547,"locationsCount":45},"100640032","the-5050-nitrous-oxide-vs-2-lidocaine-challenge-100640032","NCT07618676","The 50:50 Nitrous Oxide vs 2% Lidocaine Challenge","The 50:50 Nitrous Oxide Challenge: A Prospective Randomised Trial - Needle, Meet Your Match","Inclusion Criteria:\n\n* Subjects who have not previously received Nitrous Oxide.\n* Subjects of both sexes, aged between 18 and 65 inclusive.\n* Subjects who have signed informed consent with full disclosure; no study-related procedure may begin until the subject signs the consent form.\n\nExclusion Criteria:\n\n* Infection at the planned puncture site.\n* Pregnancy.\n* Intracranial hypertension.\n* Vitamin B12 deficiency.\n* Hemodynamic instability.\n* BMI over 35.\n* Glasgow Coma Scale (GCS) score less than 15.\n* Presence of chronic pain.\n* Neurological disorders.\n* Hematologic disorders.\n* More than two attempts at venous puncture (Subject Withdrawal Criterion).\n* Subject experienced an adverse event requiring early discontinuation (Subject Withdrawal Criterion).\n* Withdrawal of consent by the subject (Subject Withdrawal Criterion)",{"count":536,"type":22},62,[25],"The main goal of the project is to assess pain levels and patient comfort during the administration of a 50:50 Nitrous Oxide\u002FOxygen gas mixture, in comparison to the same parameters under the standard method used at our institution, which includes injecting a local anaesthetic at the site of planned puncture for central venous catheterisation.",[28,63,540],"Central Venous Catheter","2026-05-25",{"date":543,"type":37},"2026-06-01",{"date":545,"type":37},"2025-06-06",{"date":70,"type":22},{"name":548,"class":75},"Institute for Oncology and Radiology of Serbia",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":151,"phases":4,"briefSummary":558,"conditions":559,"keywords":562,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":45},"100551965","understanding-the-acute-pain-phenotype-in-patients-undergoing-surgery-100551965","NCT06466941","Understanding the Acute Pain Phenotype in Patients Undergoing Surgery","Impact of Patient Phenotypic Features on the Experience and Effectiveness of Regional Anesthesia and Postoperative Pain","Inclusion Criteria:\n\n* Age ≥ 18\n* English speaking\n* Surgical or procedural patient who will be admitted postoperatively\n* Willingness to answer psychosocial survey and\u002For audio recorded semi-structured interview\n\nExclusion Criteria:\n\n-Cognitive dysfunction that precludes communication",{"count":557,"type":22},1000,"The goal of this observational study is to learn about how regional anesthesia (numbing medication) affects pain in patients with different psychosocial phenotypes such as different levels of concern about pain, sleep issues, and anxiety, who are having surgery.\n\nThe main questions are:\n\n1. Do psychosocial factors such as concerns about pain, sleep, anxiety affect the effectiveness of regional anesthesia?\n2. Do psychosocial factors and regional anesthesia affect the amount of opioids used after surgery?\n3. Do psychosocial factors and regional anesthesia affect development of chronic postsurgical pain?",[28,560,561],"Chronic Post Operative Pain","Opioid Use",[370,563,564,565],"peripheral nerve blocks","psychosocial phenotype","pain catastrophizing","2026-05-20",{"date":568,"type":37},"2026-05-22",{"date":570,"type":37},"2024-07-03",{"date":572,"type":22},"2028-12-31",{"name":574,"class":75},"Brigham and Women's Hospital",{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":337,"enrollmentInfo":582,"targetDuration":4,"studyType":23,"phases":584,"briefSummary":586,"conditions":587,"keywords":589,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":598,"completionDateStruct":599,"leadSponsor":601,"locationsCount":4},"100637582","early-phase-1-pain-induced-by-m-cresol-as-preservative-100637582","NCT07600814","Pain Induced by m-Cresol as Preservative","Pain Induced by m-Cresol as Preservative - A Randomised Controlled Crossover-Trial in Healthy Volunteers","Inclusion criteria\n\n* Age between 18 and 70 years\n* Full legal capacity Exclusion criteria\n* Participant of another study, ongoing or within the last four weeks\n* Current medication intake (except hormonal contraception) or drug abuse\n* Female subjects: Positive pregnancy test or breastfeeding\n* Body temperature above 38°C, verified by infrared thermometer\n* Known allergic diseases, in particular asthmatic disorders and skin diseases\n* Sensory deficit, skin disease or hematoma of unknown origin in the examination of the test site",{"count":583,"type":22},18,[585],"EARLY_PHASE1","Preservatives such as m-Cresol are essential components in many subcutaneously injected medications, including insulin or human growth hormone, to prevent bacterial growth. However, clinical reports have suggested that these preservatives may cause local discomfort or pain at the injection site, which can negatively impact treatment adherence. While m-Cresol is widely used, its direct contribution to injection-site pain has not yet been investigated in a prospective clinical trial.\n\nThis study aims to investigate whether subcutaneous injection of m-Cresol at concentrations commonly used in clinical practice (0.1% and 0.25%) cause significantly more pain than a preservative-free control solution. In a randomized, double-blind crossover design, healthy volunteers will receive three separate injections in a belly fold. Participants will rate their pain every 5 seconds until it subsides. The findings will help determine if m-Cresol is a primary source of injection-site pain and could lead to the development of more comfortable drug formulations.",[176,28,588],"Healthy Volunteer Study",[590,591,592,593,594,595],"m-Cresol","Preservative","Subcutaneous Injection","Human Pain Models","Experimental Pain Models","Nociception","2026-05-15",{"date":568,"type":37},{"date":541,"type":22},{"date":600,"type":22},"2026-06-08",{"name":602,"class":75},"Medical University of Vienna",{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":609,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":611,"enrollmentInfo":612,"targetDuration":4,"studyType":23,"phases":614,"briefSummary":615,"conditions":616,"keywords":621,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":635,"locationsCount":4},"100636768","efficacy-and-safety-of-high-concentration-35-kda-hyaluronan-gel-for-herpes-zoster-associated-pain-100636768","NCT07569978","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate the Efficacy and Safety of Topical 10% High-Concentration 35 kDa Hyaluronan (HA35) Gel in Subjects With Herpes Zoster-Associated Pain","HA35-HZ","Inclusion Criteria:\n\n* Age 18-85 years, male or female\n* Clinically diagnosed with herpes zoster-associated pain (acute ZAP or PHN)\n* Baseline pain NRS score ≥5\n* Ability to understand and complete NRS assessments\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Acute bacterial skin infection at the application site\n* Use of topical analgesics or antiviral therapy within 24 hours\n* Systemic analgesic use within 6 hours\n* Known hypersensitivity to hyaluronan or gel components\n* Pregnant or lactating women\n* Severe systemic disease or malignant tumor","85 Years",{"count":613,"type":22},30,[25],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with herpes zoster-associated pain (ZAP). Eligible participants will receive a single topical application of the study gel. The primary objective is to assess rapid pain reduction within 2 minutes and 24hours after application. Secondary objectives include evaluation of analgesic duration, local tolerability, erythema improvement, and overall safety throughout the observation period. This is a minimal-risk, non-pharmacological supportive care intervention.",[617,618,619,620,28],"Herpes Zoster","Zoster-Associated Pain","Postherpetic Neuralgia","Neuropathic Pain",[622,623,624,625,617,626,619,620,321,627,628],"Hyaluronan","35 kDa Hyaluronan","HA35","Topical Gel","Zoster Pain","Non-pharmacological Intervention","Pilot Clinical Study","2026-05-05",{"date":631,"type":37},"2026-05-08",{"date":633,"type":22},"2026-05-01",{"date":180,"type":22},{"name":636,"class":399},"Nakhia Impex LLC",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":644,"enrollmentInfo":645,"targetDuration":4,"studyType":23,"phases":647,"briefSummary":648,"conditions":649,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":658,"locationsCount":45},"100632294","phase-2-a-study-of-ly4515100-in-participants-with-pain-following-third-molar-removal-100632294","NCT07511816","A Study of LY4515100 in Participants With Pain Following Third Molar Removal","A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Oral Dose of LY4515100, in Participants Experiencing Moderate-to-Severe Acute Pain Following Surgical Removal of Impacted Third Molars","Inclusion Criteria:\n\n* Participant has a body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg\u002Fm²) inclusive.\n* Participant requires extraction of 2 or more third molars, including 2 mandibular molars with partial or full bony impaction, confirmed by panoramic X-ray.\n\nExclusion Criteria:\n\n* Prior dental surgery within 60 days before screening or history of other surgical procedures that could confound surgery or postoperative procedures.\n* Diagnosis of chronic pain conditions that could confound postsurgical pain reporting in the opinion of the investigator.\n* Positive urine drug screen or alcohol test during screening or on the day of surgery.\n* Evidence or history of any other clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, or neurologic diseases, in the opinion of the investigator, within the last 5 years.\n* History of malignancy of any organ system treated or untreated, within 5 years prior to consent. The only exceptions are previous in situ carcinoma of the cervix, localized basal cell carcinoma of the skin, or localized squamous carcinoma of the skin if the participant has been treated and is considered cured.","40 Years",{"count":646,"type":22},212,[313],"The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.",[28,650,651,652],"Molar","Molar, Third","Surgery, Oral","2026-04-27",{"date":633,"type":37},{"date":656,"type":37},"2026-04-01",{"date":447,"type":22},{"name":659,"class":399},"Eli Lilly and Company",{"id":661,"slug":662,"hasResults":12,"nctId":663,"briefTitle":664,"officialTitle":665,"acronym":666,"eligibilityCriteria":667,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":668,"targetDuration":4,"studyType":23,"phases":670,"briefSummary":671,"conditions":672,"keywords":673,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":45},"100635510","the-effect-of-shotblocker-on-pain-anxiety-and-satisfaction-during-peripheral-intravenous-catheterization-100635510","NCT07553624","The Effect of ShotBlocker on Pain, Anxiety, and Satisfaction During Peripheral Intravenous Catheterization","The Effect of Shotblocker on Pain, Anxiety, and Satisfaction During Peripheral Intravenous Catheterization: A Randomized Controlled Trial","SB-PIVC","Inclusion Criteria:\n\nIndividuals aged 18 years and older Patients requiring peripheral intravenous catheterization Patients who are conscious and able to communicate Patients who agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\nPatients with cognitive impairment or inability to communicate Patients with a history of chronic pain or current use of analgesics Patients with dermatological conditions or wounds at the catheterization site Patients who previously experienced peripheral intravenous catheterization within the last 24 hours Patients who refuse to participate in the study",{"count":669,"type":22},100,[25],"This randomized controlled trial aims to evaluate the effect of the ShotBlocker device on pain, anxiety, and patient satisfaction during peripheral intravenous catheterization (PIVC). Peripheral intravenous catheterization is a commonly performed procedure in clinical settings and is often associated with pain and anxiety, which may negatively affect patient experience.\n\nThe ShotBlocker is a simple, non-pharmacological device designed to reduce pain by applying pressure and sensory stimulation at the injection site. Participants will be randomly assigned to either the intervention group, where the ShotBlocker will be used during the procedure, or the control group, where routine care will be provided.Pain will be assessed using the Visual Analog Scale (VAS). Anxiety and patient satisfaction will be evaluated using a visual analog-based scale supported , combining features of the Visual Analog Scale and the Wong-Baker Faces Scale, with scores ranging from 0 to 10. The findings of this study are expected to contribute to evidence-based nursing practices by providing an effective, low-cost, and non-invasive method for reducing procedural discomfort and improving patient experience during PIVC.",[28,63],[674,675,176,63,676],"Peripheral Intravenous Catheterization","ShotBlocker","Patient Satisfaction","2026-04-23",{"date":679,"type":37},"2026-04-28",{"date":681,"type":22},"2026-04-18",{"date":683,"type":22},"2026-05",{"name":685,"class":75},"Kirsehir Ahi Evran Universitesi"]